Compare OSW & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OSW | ANIP |
|---|---|---|
| Founded | 2017 | 2001 |
| Country | Bahamas | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.0B |
| IPO Year | N/A | N/A |
| Metric | OSW | ANIP |
|---|---|---|
| Price | $20.02 | $81.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $24.33 | ★ $99.29 |
| AVG Volume (30 Days) | ★ 478.6K | 468.6K |
| Earning Date | 10-29-2025 | 11-07-2025 |
| Dividend Yield | ★ 1.00% | N/A |
| EPS Growth | ★ 40.79 | N/A |
| EPS | 0.70 | ★ 1.67 |
| Revenue | ★ $936,080,000.00 | $826,880,000.00 |
| Revenue This Year | $8.68 | $43.41 |
| Revenue Next Year | $8.04 | $9.66 |
| P/E Ratio | ★ $28.63 | $48.82 |
| Revenue Growth | 7.27 | ★ 48.87 |
| 52 Week Low | $14.21 | $52.50 |
| 52 Week High | $23.49 | $99.50 |
| Indicator | OSW | ANIP |
|---|---|---|
| Relative Strength Index (RSI) | 41.77 | 36.38 |
| Support Level | $19.60 | $77.99 |
| Resistance Level | $20.86 | $85.09 |
| Average True Range (ATR) | 0.71 | 2.61 |
| MACD | -0.02 | 0.19 |
| Stochastic Oscillator | 48.17 | 41.60 |
OneSpaWorld Holdings Ltd is an operator of health and wellness centers onboard cruise ships and an operator of health and wellness centers at destination resorts all over the world. It offers a suite of premium health, fitness, beauty, and wellness services and products. The services provided by the company include body, salon, and skin care services and products, fitness classes and personal fitness training and pain management, detoxifying programs, and comprehensive body composition analyses among others. The company has only one single segment of Maritime and Destination Resorts.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.